BUY SUPERDROL (METHASTERONE) (50 MG/ML – 10 ML)
MAIN PRODUCT DESCRIPTION
Product Overview & Pharmaceutical Specifications
Superdrol (Methasterone) 50 mg/ml – 10 ml is presented in the supplied information as an anabolic-androgenic steroid preparation containing methasterone, also known as methyldrostanolone. The source describes methasterone as a synthetic anabolic hormone and discusses its historical development and relationship to other anabolic steroids.
The supplied product presentation identifies a concentration of 50 mg/ml and a quantity of 10 ml. The source associates the product with Spectrum Pharma.
Because the supplied information does not provide a complete formulation specification for the stated presentation, additional technical characteristics have not been invented.
Product Specifications
Product: Superdrol
Active Ingredient: Methasterone (Methyldrostanolone)
Strength: 50 mg/ml
Pack Size: 10 ml
Dosage Form: Injectable preparation, according to product presentation
Drug Class: Anabolic-androgenic steroid
Brand/Manufacturer stated: Spectrum Pharma
Route: Not specifically supplied
Market Status: Not supplied
Molecular Formula: Not supplied
Molecular Weight: Not supplied
CAS Number: Not supplied
Storage: Not supplied
Pharmacological Classification
Methasterone is an anabolic-androgenic steroid (AAS). The supplied source compares its properties with drostanolone (Masteron), another steroid associated with the dihydrotestosterone family.
Anabolic-androgenic steroids exert their principal biological effects through the androgen receptor, an intracellular receptor involved in regulating gene transcription in androgen-responsive tissues.
Androgen-receptor signalling can influence skeletal muscle, bone, reproductive tissues, skin and other organs. Consequently, anabolic steroids should not be regarded as compounds acting exclusively on muscle tissue.
Methasterone and Methyldrostanolone
Methasterone is also referred to as methyldrostanolone. The supplied material highlights its similarity to drostanolone and describes its historical development as an anabolic steroid.
The source states that pharmaceutical research involving methasterone dates back several decades and associates its early development with Syntex. It also places the compound historically alongside other anabolic steroids that appeared during the same general period.
These historical details provide context for the development of methasterone but do not establish a current therapeutic indication for the specific product presented here.
Historical Product Background
According to the supplied information, methasterone attracted renewed attention in the consumer market during the early 2000s after appearing in products marketed as hormone or anabolic supplements.
The source further describes regulatory action against Superdrol-containing products in the United States and states that methasterone subsequently became subject to legal restrictions.
Because no current regulatory documentation has been supplied for the 50 mg/ml Spectrum Pharma presentation, these historical statements should not be treated as a current EU or country-specific regulatory classification.
For European e-commerce purposes, the applicable regulatory status must be determined separately for the country in which the product would be marketed or supplied.
Relationship to Drostanolone
The supplied source specifically compares methasterone with drostanolone (Masteron). Both are androgenic steroid compounds, and methasterone is commonly described as a methylated derivative related to the drostanolone structure.
Structural similarity does not mean that two compounds have identical pharmacological, pharmacokinetic or safety characteristics. Each active substance should therefore be evaluated according to its own evidence rather than assuming that information about drostanolone automatically applies to methasterone.
Anabolic-Androgenic Activity
The principal scientific interest in methasterone concerns its anabolic-androgenic activity.
Activation of androgen receptors can influence protein metabolism and gene expression in androgen-responsive tissues. These mechanisms form part of the biological basis for the anabolic and androgenic effects associated with this class of compounds.
However, the supplied information does not provide sufficient clinical evidence to establish a specific therapeutic benefit from this particular 50 mg/ml preparation.
Claims about muscle growth, strength, body composition or athletic performance should therefore not be presented as guaranteed outcomes.
Medical and Clinical Context
The supplied information does not provide a current, verified therapeutic indication for Superdrol or methasterone.
The historical description focuses primarily on its development and use as an anabolic hormone rather than an established modern pharmaceutical treatment. Consequently, no disease-specific indication has been added.
The product should not be marketed as an approved treatment for muscle wasting, osteoporosis, hormonal deficiency, athletic performance or body composition unless an appropriate regulatory authority and official product documentation specifically support such an indication.
Safety Considerations
The supplied material provided does not include a complete adverse-reaction profile, contraindication list, drug-interaction section or patient-monitoring requirements for methasterone.
These omissions are important because anabolic-androgenic steroids can have systemic effects involving endocrine, cardiovascular, hepatic, reproductive and metabolic systems.
The absence of a complete safety profile in the supplied material should not be interpreted as evidence that methasterone is safe or free of significant adverse effects.
No claims such as “safe”, “side-effect free”, “liver safe” or “low risk” have therefore been added.
Regulatory Considerations
The source contains historical statements concerning the regulatory treatment of Superdrol and methasterone in the United States, including claims about FDA action and subsequent restrictions.
Those statements have not been expanded into current legal claims because regulatory status can change and differs between jurisdictions.
No EU-wide marketing authorisation, national European marketing authorisation or country-specific legal classification was provided for this product. Therefore, Superdrol should not be described as EU-approved or legally saleable throughout Europe.
The appropriate regulatory status should be checked against the competent authority in each relevant market before publication or commercial distribution.
Product Presentation
The supplied product title specifies:
Superdrol (Methasterone) – 50 mg/ml – 10 ml.
The product is presented as an injectable preparation. No detailed information concerning the vehicle, excipients, sterility specifications, vial type or manufacturing standards was provided.
These details should be obtained from the current manufacturer documentation rather than inferred.
Manufacturer and Brand Information
The supplied source identifies Spectrum Pharma in connection with Superdrol.
No additional verified information concerning manufacturing facilities, GMP certification, batch-release testing, certificate of analysis or regulatory authorization was supplied.
Dosage and Administration
The supplied material does not provide a reliable, product-specific dosing regimen for the 50 mg/ml injectable presentation.
No dosing schedule has therefore been created or inferred. The stated concentration of 50 mg/ml describes the product strength and should not be interpreted as a recommended individual dose.
Use of anabolic-androgenic steroids should not be undertaken without appropriate medical assessment and professional supervision.
Storage
No specific storage conditions were provided in the supplied source.
Storage should therefore follow the manufacturer’s current official label and technical documentation. A temperature range has not been invented.
Important Pharmaceutical Disclaimer
Superdrol (Methasterone) is described in the supplied information as an anabolic-androgenic steroid. The historical and bodybuilding-oriented claims in the source have not been converted into guaranteed clinical or performance claims.
The information above is based solely on the product material provided. It does not establish clinical efficacy, safety, regulatory approval or an appropriate human treatment regimen.
Before commercial publication, the product’s exact formulation, active concentration, manufacturer documentation, regulatory classification and current country-specific legal status should be verified.
